Amphista Therapeutics names executives to drive clinical development

Amphista Therapeutics Ltd has appointed three executives to drive the advancement of its therapies based on targeted protein degradation into the clinic. They are: Lisa Butler, senior vice president of clinical operations, Alexandra Sevko, vice president of translational science and Nicola Lindsay, head of project and portfolio management. The executives bring decades of experience in early-and late-stage development at leading biotech and pharma companies, including AstraZeneca and Adaptimmune, to support Amphista’s lead programme, AMX-883, for acute myeloid leukaemia. Dr Butler’s experience in clinical programme delivery will support Amphista’s clinical readiness; Dr Sevko brings expertise in immuno-oncology and translational research; and Ms Lindsay has led projects from lead optimisation through to clinical proof-of-concept across multiple therapeutic areas.

Amphista Therapeutics announced the appointments on 23 October 2025.